Treatment of Chronic Phase CML: A Decade of Progress
Over the last decade, CML has become a curable chronic disease for most patients, and many therapeutic options are now available.
Diagnosis & Disease Information
Myelofibrosis Symptoms, Treatment, and Quality of Life
This fact sheet on myelofibrosis leukemia symptoms, treatment options and quality of life issues helps newly-diagnosed patients.
Therapy-Related Leukemia Risk Varied From 1975 to 2008
Risk after chemotherapy varies depending on initial cancer and treatment practices.
Review of Consensus Recommendations on Plasma Cell Leukemia
The International Myeloma Working Group recommends bortezomib and stem-cell transplantation for treatment of plasma cell leukemia.
FDA: Gleevec (Imatinib) Approved for Pediatric Ph+ ALL
The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat children newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia.
Alkylating Agent Linked to Therapy-Related Leukemia
Significant reductions seen with successive generations of Hodgkin lymphoma therapy.
Mechlorethamine Topical Gel Effective in Mycosis Fungoides
A novel topical chemotherapy, mechlorethamine hydrochloride, 0.02%, gel, is safe and effective in the treatment of patients with mycosis fungoides, the most common type of cutaneous T-cell lymphoma.
Liposomal Daunorubicin Plus FLAG Induces Best Pediatric Relapsed AML Outcomes to Date
Treatment with liposomal daunorubicin plus fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) has resulted in the best outcome for children with relapsed core-binding factor acute myeloid leukemia.
Obese Patients with Chronic-Phase CML Experience Delayed Responses and Lower Response Rates to First-Line Imatinib
Elevated body mass index is also associated with delayed cytogenetic and major molecular responses among patients treated with imatinib for chronic phase CML.
Telintra Granted Orphan Drug Designation for MDS
Telik announced that ezatiostat HCl (Telintra) has been granted orphan drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS).
- Loading...
Loading...
Loading... 
Loading...